Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

BUY Jyothy Laboratories - With multiple triggers, outlook 'bright': Anand Rathi Institutional Research

Posted On: 2016-08-16 20:43:27

Jyothy Laboratories - With multiple triggers, outlook 'bright'; upgrading to a Buy with a target procee of Rs 360

Jyothy Laboratories' Q1 results were ahead of our estimates: 10% volume growth and a strong 370-bp expanded EBITDA margin driving 78% yoy profit growth. The broad-based volume growth and strong operating-margin tailwinds (driven by the gross margin) reflect strengthening business fundamentals. Multiple triggers (a better monsoon driving rural demand pickup, monetisation of its land assets, and Henkel possibly exercising its option to buy a 26% stake) could offer further potential. Hence, we upgrade the stock to a Buy.

A strong Q1 showing. Revenue grew 9% yoy to Rs. 4.4bn (slightly lower than our estimated 11%), aided by 10% volume growth. EBITDA grew 37% yoy to Rs. 791m. The EBITDA margin expanded ~370bps yoy to 18%, primarily driven by lower employee expenses (down 230bps yoy) and a higher gross margin (up 150bps yoy). Adj. PAT grew 78% to Rs. 459m (lower than our Rs. 555m estimate), hit by higher taxes (a 24.6% rate in Q1, vs. no taxes estimated on expectation of amalgamation of the loss-suffering subsidiary).

Margin tailwinds to ensure strong earnings growth. The flagship brand Ujala clocking 10% growth in Q1 reflects that management efforts to drive growth in the mature soap & detergent category are yielding results. Increased brand investments, innovation and distribution initiatives in the non-south market should help sustain the revenue momentum. Further, cost-saving measures, easing input costs and tax benefits should help drive a 47% earnings CAGR over FY16-18.

Valuation. We have tweaked our estimates to reflect taxes in H1 FY17, while factoring in the tax benefits from the amalgamation with the loss-saddled (Rs. 3bn) subsidiary JCM in H2 FY17 and FY18. Thus, we raise our FY18e EPS 16% while reducing the FY17e EPS 13%. We upgrade the stock to a Buy with a revised price target of Rs. 360, based on 27x FY18e vs. Rs. 340 earlier (30x FY18e). Risks: A steep rise in input costs, weaker demand and keener competition in its Home and Personal care sub-segments.

Shares of JYOTHY LABORATORIES LTD. was last trading in BSE at Rs.282.6 as compared to the previous close of Rs. 285.25. The total number of shares traded during the day was 8837 in over 369 trades.

The stock hit an intraday high of Rs. 286.95 and intraday low of 282.6. The net turnover during the day was Rs. 2515275.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Technical View on Crude Oil - Target - $ 56 to $ 58 , (CMP - 3640 / $ 54.35): Angel Broking
Ambuja Cements - 4QCY16 Result Update - Better Operating Performance on Higher Realizations - Reliance Securities
Cement - 3QFY17 Results Review - A Quiet Quarter - Impacted by Cash Crunch - Reliance Securities
Britannia Industries - Initiating Coverage - Betting on Premiumization, Distribution and Cost optimization - Reliance Securities
Srikalahasthi Pipes - Initiating Coverage - Piping Gains - Reliance Securities
NCC - Initiating Coverage - A Solid Play in Infrastructure Pickup - Reliance Securities
TCS Buyback - Update - Angel Broking
Nestle India - 4QCY16 Result Update - Better Times Awaited; Maintain REDUCE - Reliance Securities
Kalpataru Power Transmission - 3QFY17 Result Update - Growth Momentum Continues; Strong Order Book Offers High Revenue Visibility - Reliance Securities
NALCO - 3QFY17 Result Update - Strong Performance on Higher Volume, Realizations - Reliance Securities
Further Re-rating of HDFC Bank to come from Core earnings growth: Angel Broking
Cadila Healthcare - no 483 For Moraiya plant: Angel Broking
GlaxoSmithKline Consumer - 3QFY17 Result Update - Weak Demand Accentuated by Demonetization - Reliance Securities
MOIL - 3QFY17 Result Update - Stellar Performance to Continue; Upgrade to BUY - Reliance Securities
Techno Electric & Engineering - 3QFY17 Result Update - Strong Quarter; Order Pipeline Remains Robust - Reliance Securities
J. Kumar Infraprojects - 3QFY17 Result Update - Decent Performance on Execution Ramp-up - Reliance Securities
Views on Sun Pharmaceutical Industries Limited 3QFY2017 Results: Angel Broking
All the queries put to rest at Infosys Press Conference: Angel Broking
Hindustan Zinc - 3QFY17 Result Update - Higher Zinc Prices Aid Earnings, but Valuation Expensive; Reiterate REDUCE - Reliance Securities
Mangalam Cement - 3QFY17 Result Update - Robust Volume Growth Aids Performance - Reliance Securities
Power Grid Corporation - 3QFY17 Result Update - Higher Capitalization Continues to Drive Growth - Reliance Securities
HeidelbergCement - 3QFY17 Result Update - A Quiet Quarter; Expect Improvement Ahead - Reliance Securities
Bank of Baroda - 3QFY17 Result Update - Asset Quality Pressure Continues to Persist; Downgrade to HOLD - Reliance Securities
Steel Authority of India - 3QFY17 Result Update - Higher Raw Material Cost & Lower Volume Dent Margins - Reliance Securities
Hindalco - 3QFY17 Result Update - Strong Performance Continues; Valuation Pricey - Reliance Securities
KNR Constructions - 3QFY17 Result Update - Beats Estimates on Better Execution - Reliance Securities
Ahluwalia Contracts - 3QFY17 Result Update - Strong Performance on All Parameters - Reliance Securities
NBCC - 3QFY17 Result Update - Better Operating Performance; Prospect Remains Bright - Reliance Securities
Goodluck India - 3QFY17 Result Update - Subdued Quarter; Better Times Expected as Input Prices Stabilize - Reliance Securities
Alkem Laboratories - 3QFY2017 Result Update - Angel Broking
Bank Of Baroda - 3QFY2017 Result Update - Angel Broking
Garware Wall Ropes - 3QFY2017 Result Update - Angel Broking
Views on GlaxoSmithKline Pharmaceuticals Limited 3QFY2017 Results: Angel Broking
J.K. Cement - 3QFY17 Result Update - Healthy Operating Performance amid Dismal Volume Growth - Reliance Securities
Jubilant FoodWorks - 3QFY17 Result Update - Too Fast Too Soon; Downgrade to HOLD - Reliance Securities
Sonata Software - 3QFY17 Result Update - Unimpressive Show; IITS Revenue Disappoints - Reliance Securities
JK Lakshmi Cement - 3QFY17 Result Update - Better Operating Performance on Cost Savings - Reliance Securities
Dr. Reddy's Laboratories - 3QFY17 Result Update - Long-term Fundamentals Remain Intact; Headwinds to Persist in the Near-term - Reliance Securities
Titan Company - 3QFY17 Result Update - Dazzles in Dark Times - Reliance Securities
Union Bank of India - 3QFY17 Result Update - Asset Quality Pressure Persists; Downgrade to HOLD - Reliance Securities
Ramco Cements - 3QFY17 Result Update - Healthy Operating Performance Continues amid Realizations Pressure - Reliance Securities
Hexaware Technologies - 4QCY16 Result Update - Solid Quarter, Deal Wins Strong; Client-Specific Issue A Negative - Reliance Securities
eClerx Services - 3QFY17 Result Update - Disastrous Performance on All Counts - Reliance Securities
Punjab National Bank - 3QFY17 Result Update - Asset Quality Pressure Recedes; Reiterate HOLD - Reliance Securities
HeidelbergCement India: 3QFY17 Result: FIRST CUT - Reliance Securities
Views on Lupin Limited 3QFY2017 Results: Angel Broking
Skipper - 3QFY17 Result Update - Transmission Capex Play; On Right Track - Reliance Securities
NTPC - 3QFY17 Result Update - Improving Performance on Operational Metrics - Reliance Securities
Navkar Corporation - 3QFY17 Result Update - Stable Performance; Strong Volume Growth on the Cards - Reliance Securities
Views on IPCA Laboratories Ltd 3QFY2017 Results: Angel Broking


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017